Download Library

Document Type

The mechanisms of increasing outflow facility by AR13324M in human eyes

Effectiveness of AR-13154 Monotherapy and Combination Therapy in Animal Models
of Wet Age-related Macular Degeneration and Proliferative Diabetic Retinopathy

2016 Proxy Statement

2015 Annual Report

Visualization of tissue response to netarsudil in living mouse eyes

Anti-fibrotic Effects of AR-13324 in a
3D Bioengineered Human Trabecular
Meshwork Model

Topical Administration of a ROCK/NET
Inhibitor Promotes Retinal Ganglion Cell
Survival and Axon Regeneration

The Mechanisms of Increasing Outflow Facility
by AR-13324M in Human Eyes

AR-13324 Ophthalmic Solution 0.02%: Topline Results of Two Phase 3 Clinical Studies in Patients with Open Angle Glaucoma and Ocular Hypertension

Fixed-dose combination of AR-13324 and
latanoprost: a double-masked, 28-day, randomised,
controlled study in patients with open-angle
glaucoma or ocular hypertension